Taltz (Eli Lilly) is expected to face US biosimilar competition from 2030. Lilly 10-K: US compound patent 2030; US biologics data protection runs to 2028.
Taltz's US exclusivity date is based on company guidance. The date comes from the company's own filings or guidance. Secondary patents, new formulations or litigation can still move it. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
Among past biologics facing biosimilars: Humira's US sales fell to 65% of their 2022 level in its first full year of biosimilars (2023) and 16% two years later; Stelara's US sales fell to 57% of their 2024 level in its first full year of biosimilars (2025). See how past cliffs played out →
In clinical trials Samsung Bioepis started a first trial of its Taltz biosimilar in August 2026. Celltrion and Alvotech have also announced programs.
| Company (product) | Stage |
|---|---|
| Samsung Bioepis (SB35) | Phase 1 started Aug 2026 |
| Celltrion (CT-P52) | Early development |
| Alvotech (AVT28) | Early development |
Checked September 2026. Sources: Pearce IP: Samsung Bioepis trial · BioPatrika: Taltz biosimilars
Taltz is 5.5% of Eli Lilly's 2025 revenue ($3.6B of $65.2B). With Trulicity, Verzenio, Mounjaro and Zepbound, the drugs tracked here add up to 77% of Eli Lilly's revenue losing US exclusivity by 2036.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Taltz is highlighted.